iBio Inc (USD)
IBIO
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range2.17 | 2.29
52-Wk Range- | -
Last Close2.31
Mkt Cap (m)276.73
Dividend yield-
ISINUS4510332038
Volume6,960,547.00
Exchange VenueASE

Company Profile

iBio Inc is a biotechnology company. It is engaged in commercializing its proprietary platform technologies, iBioLaunch for vaccines and therapeutic proteins & iBioModulator for vaccine enhancement and developing select product candidates.

Key Information
Price/Earning-
Price/Book69.93
Price/Sales70.80
P/CF-
Rev Growth (3 year avg)28.64
EPS Growth (3 year avg)-
Operating Margin % -782.36
Net Margin %-871.80
Return on Equity-191.67
Debt/Equity10.10

Documents

Prospectus
en 17/06/2020
Annual Report
en 30/06/2019

Please refer to the below issuer website for further documents.

https://www.biospace.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.211.850.950.390.442.02
Operating Income (m)-3.84-6.67-9.89-14.27-14.23-15.79
Net Income (m)-3.67-6.63-9.76-14.53-16.11-17.59
Basic EPS-0.60-0.90-1.20-1.60-1.54-0.94
Avg. Diluted Shares Outstanding (m)6.307.158.108.9110.6318.93
Balance Sheet
USD201420152016201720182019
Current Assets (m)3.9110.1223.918.5716.294.81
Non Current Assets (m)2.582.3727.6927.4426.8025.78
Total Assets (m)6.4912.4951.6036.0143.0830.59
Current Liabilities (m)0.401.262.292.012.043.46
Total Liabilities (m)------
Total Equity (m)6.1011.239.948.9116.172.46
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-4.12-4.73-8.07-13.16-13.48-13.98
Capital Expenditure (m)-0.26-0.22-0.07-1.59-1.08-0.99
Figures are quoted in USD unless stated otherwise
-0.03 (-1.30%)
$
2.28
Last Price